WHO adds four anti-tuberculosis medicines to its list of prequalified medicines

NewsGuard 100/100 Score

The World Health Organization (WHO) has added four anti-tuberculosis medicines to its list of prequalified products.

Manufactured by the generic producer MacLeods of India, these medicines will increase the choice of quality products available to procurement agencies to tackle the disease.

One of the products, Cycloserine, is particularly important because it is a second-line medicine, necessary to treat tuberculosis that is resistant to standard treatment. Cycloserine is the first such product to be included in the list. There is also a fixed-dose combination – ethambutol + isoniazid – which is the first product combining these two basic medicines to be prequalified. The other two medicines are Ethambutol and Pyrazinamide.

The four medicines are the first TB products in two years to be added to the list of prequalified medicines. Their addition to the list reflects considerable quality improvement made by manufacturers, and an increasing interest in being part of the prequalification programme.

The addition of these four medicines will reinforce efforts to scale up access to anti-tuberculosis medicines in high-burden areas and in countries which may have only limited capacity to control and monitor pharmaceuticals.

Product assessment reports on the quality and bioequivalence of these newly prequalified products and manufacturing site inspection findings will soon also be published. These procedures make the WHO prequalification process the most transparent of all similar quality assurance programmes to date.

Recent figures released by WHO put the number of TB cases in 2005 at 8,787,000. An estimated 1.6 million people died of the disease in 2005, 195,000 of them people living with HIV.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals lasting lung damage in tuberculosis survivors